Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

3.18
Delayed Data
As of Feb 17
 -0.01 / -0.31%
Today’s Change
2.83
Today|||52-Week Range
9.02
-22.06%
Year-to-Date
Merrimack (MACK): What Awaits the Stock in Q4 Earnings?
Feb 17 / Zacks.com - Paid Partner Content
3 Stocks Begging for a Buyout
Feb 11 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close3.19
Today’s open3.19
Day’s range3.15 - 3.23
Volume1,123,509
Average volume (3 months)3,540,602
Market cap$412.2M
Dividend yield--
Data as of 3:59pm ET, 02/17/2017

Growth & Valuation

Earnings growth (last year)-66.25%
Earnings growth (this year)+12.28%
Earnings growth (next 5 years)+5.61%
Revenue growth (last year)-13.14%
P/E ratioNM
Price/Sales9.86
Price/Book--

Competitors

 Today’s
change
Today’s
% change
AVDLAvadel Pharmaceutica...-0.07-0.71%
CARACara Therapeutics In...+0.23+1.58%
TLGTTeligent Inc+0.13+1.75%
MYOKMyoKardia Inc-0.20-1.54%
Data as of 4:00pm ET, 02/17/2017

Financials

Next reporting dateMarch 2, 2017
EPS forecast (this quarter)-$0.21
Annual revenue (last year)$89.3M
Annual profit (last year)-$148.0M
Net profit margin-165.76%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer
Richard Peters
Head-
Corporate Operations
William M. McClements
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs